The Recall Desk
LowFDA (Drugs)·D-0175-2021·Announced 2021-01-06

US Compounding Recalls Neostigmine Methylsulfate Syringes Due to Missing Labels

US Compounding Inc is recalling 1,640 syringes of Neostigmine Methylsulfate Injection because they are missing labels. The product was distributed nationwide.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The issue is a packaging/labeling defect (missing label) without reported injuries.

Plain-English summary

US Compounding Inc is recalling 1,640 syringes of Neostigmine Methylsulfate PF Injection, 5 mg/5 mL, 5 mL Single Use Syringes. The recall is due to a labeling defect where the product is missing its label. The affected lot is 20202109@3 with a beyond-use date of March 20, 2021.

The product is intended for hospital and office use only. It was distributed nationwide. The NDC for the product is 62295-3324-05.

Healthcare facilities should stop using the affected product and contact US Compounding Inc for further instructions. Consumers should not use this product if they have it in their possession.

The recalled product

Product
Neostigmine Methylsulfate PF Inj. 5 mg/5 mL, 5 mL Single Use Syringes, Hospital/Office Use Only. US Compounding 1270 Don's Lane Conway, AR 72032 (800) 718-3588 NDC 62295-3324-05
Manufacturer
US Compounding Inc
Affected units
1,640

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • Lot: 20202109@3 BUD: 3/20/2021

Distribution

Distributed nationwide across the United States.